BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Ali Alhoshani¹
Fahad O Alatawi¹
Fawaz E Al-Anazi¹
Ibraheem M Attafi²
Asad Zeidan³
Abdelali Agouni⁴
Heba M El Gamal⁴
Licia S Shamoon⁴
Sarah Khalaf⁴
Hesham M Korashy⁴

¹Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;

²Poison Control & Medical Forensic Chemistry Center, Jazan Health Affairs, Jazan, Saudi Arabia; ³Department of Biomedical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar; ⁴Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar

Introduction: Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation.

Methods: Breast cancer cell lines with different molecular subtypes (MDA-MB-231, MCF-7, and SKBR-3) were treated with different concentrations of VCX for indicated time points. The expression of cell proliferative, apoptotic, and autophagy genes was determined by qRT-PCR and Western blot analyses. In addition, the percentage of MDA-MB-231 cells underwent apoptosis, expressed higher oxidative stress levels, and the changes in the cell cycle phases were determined by flow cytometry.

Results: Treatment of human breast cancer cells with increasing concentrations of VCX caused a significant decrease in cells growth and proliferation. This effect was associated with a significant increase in the percentage of apoptotic MDA-MB-231 cells and in the expression of the apoptotic genes, caspase 3, caspase 7, and BAX, with inhibition of anti-apoptotic gene, BCL-2 levels. Induction of apoptosis by VCX treatment induced cell cycle arrest at G0/G1 phase with inhibition of cell proliferator genes, cyclin D1 and E2F1. Furthermore, VCX treatment increased the formation of reactive oxygen species and the expression level of autophagy markers, Beclin 1 and LC3-II. Importantly, these cellular changes by VCX increased the chemo-sensitivity of MDA-MB-231 cells to doxorubicin.

Discussion: The present study explores the molecular mechanisms of VCX-mediated inhibitory effects on the growth and proliferation of TNBC MDA-MB-231 cells through the induction of apoptosis, cell cycle arrest, and autophagy. The study also explores the role of BCL-2 as a novel targeted therapy for breast cancer.

Keywords: venetoclax, MDA-MB-231 cells, breast cancer, apoptosis, BCL-2, cell cycle, autophagy

Introduction

Breast cancer (BC) is one of the highest leading causes of cancer deaths.^{1,2} BC affects one in eight women and almost one million new cases of BC are identified every year worldwide.³ Thus, BC causes serious public health problems owing to its complexity, incidence, prevalence, mortality, heterogeneity, and, ultimately, the economic impact of therapy. The primary biomarkers for BC are the estrogen

Correspondence: Hesham M Korashy
Professor of Pharmacology and Toxicology, College of Pharmacy, Qatar University, Doha 2713, Qatar
Tel +974 4403 5592
Email hkorashy@qu.edu.qa

receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The expression levels of these hormonal receptors allow for classification of BC into subtypes, with tumors lacking in ER, PR, and HER2 expression are classified as triple-negative breast cancer (TNBC).⁴ Unlike other cancer types, research has yet to confirm targeted therapy for TNBC, and the specific molecular underpinnings of the aggressiveness displayed by TNBC are not well understood. This consistently yields unfavorable medical prognoses and complicated treatment schemes.

Due to the overexpression of BCL-2 in BC, it was recognized as an effective prognostic marker for TNBC. Overexpression of BCL-2 occurs in approximately 41% of TNBC cases.⁵ Research has outlined a relationship between BCL-2 expression and increased chance of survival in TNBC patients,⁶ but the way in which BCL-2 could function as a therapeutic target for BC is not concrete. Several compounds responsible for targeting various components of the BCL-2 protein family are now being investigated in preclinical studies, along with clinical trials of TNBC. Among which, BH3 mimetic drugs hold the most significant level of potential in this respect.⁷ Notable studies have found that BH3 synthetic compounds display affinities for the pro-survival proteins. Among these BH3 mimetic compounds, venetoclax (VCX) received accelerated USA FDA approval for the treatment of acute lymphocytic leukemia in 2016 and chronic lymphocytic leukemia and lymphoma in 2019.⁸ VCX is a potent, selective, and orally available BH3 mimetic that serves as a BCL-2 inhibitor. VCX facilitates the restoration of the apoptotic capacity of cancer cells by displacement of BIM, a pro-apoptotic BCL-2 family protein, resulting in activation of apoptosis.⁹ With increased BCL-2 expression in BC and particularly TNBC, VCX may become a potential therapy for BC; however, the effects and the mechanisms mediating VCX anti-cancer activity need to be explored.

Although few previous studies have reported that VCX in combination with chemotherapeutic agents such as doxorubicin¹⁰ or dasatinib¹¹ increased the apoptosis levels in different breast cancer cell lines, these studies lack the mechanisms involved particularly the role of autophagy and oxidative stress. Therefore, the current study aimed to test hypothesize that inhibition of BCL-2 signaling pathway by VCX induces BC apoptosis and autophagy-associated cell death. To test this hypothesis, we generally evaluated the potential effect of VCX on cell proliferation of three different BC cells with different molecular subtypes and investigated the molecular mechanisms of

apoptosis, cell cycle, autophagy, and oxidative stress in TNBC MDA-MB-231 cells.

Materials and Methods

Chemicals

Venetoclax and doxorubicin were obtained from LC laboratories (Woburn, MA, USA). Bovine serum albumin and protease cocktail inhibitor reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA). High-Capacity cDNA Reverse Transcription kit and SYBR[®] Green PCR Master Mix were obtained from Applied Biosystems[®] (Foster City, CA, USA). Primary antibodies to target proteins and peroxidase-conjugated antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Chemiluminescence Western blot detection kits, Muse[®] Count & Viability Kit, Muse[®] Annexin V & Dead Cell Kit, Muse[®] Caspase 3/7 Kit, Muse[®] MitoPotential Kit, Muse[®] Oxidative Stress Kit, and Muse[®] Cell Cycle Kit were all obtained from EMD Millipore Co. (Billerica, MA, USA). All other chemicals were obtained from Fisher Scientific Co. (Toronto, ON, Canada).

Cell Lines Culture and Treatment

Human breast cancer cell lines, MCF-7 (ER+), SKBR-3 (HER2+), and MDA-MB-231 (TNBC), were obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were grown in Dulbecco's Modified Eagle Medium with phenol red supplemented with Fetal Bovine Serum (FBS, 10%) and Antibiotic-Antimycotic (1%) using standard cell culture methods. Venetoclax and doxorubicin were prepared fresh in dimethyl sulfoxide (DMSO) before each experiment. The same concentration of DMSO was used as a control. Briefly, cells were seeded on 6- or 12-well culture plates to reach 80% confluency, after which they were treated for 24 h with DMSO or VCX (10, 25, and 50 μ M), unless otherwise specified.

Cell Viability and Proliferation Assay

BC cell proliferation was determined using Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA), according to manufacturer's instruction, standardized to control probes as described previously.¹² In brief, SKBR-3, MCF-7, and MDA-MB-231 cells were treated with a wide range of VCX concentrations (0.5, 1, 2.5, 5, 10, 25, 50, and 100 μ M).^{10,13} After 24 h, the cells were collected by trypsinization and then incubated with

Muse[®] Count & Viability Kit, EMD Millipore Co. (Billerica, MA, USA). Both viable and non-viable cells were quantified, and the half-maximal inhibitory concentrations (IC₅₀) were calculated using Sigma Stat[®] Systat Software Inc. (San Jose, CA, USA).

Mitochondrial Membrane Potential and Cellular Plasma Membrane Permeabilization Assay

The changes in mitochondrial potential and cellular plasma membrane permeabilization, early hallmarks of apoptosis and cell death, were determined with Muse[®] Mitochondrial Kit (Millipore) as described previously.¹⁴ Briefly, MDA-MB-231 cells treated for 24 h with VCX were incubated with MitoPotential working solution for 20 min at 37°C in 5% of CO₂ incubator. After incubation, 5 µL of Muse[®] MitoPotential 7-ADD reagent was added and incubated for 5 min at room temperature. The percentage of four cell populations; live (mitopotential⁺/7-AAD⁻), depolarized live (mitopotential⁻/7-AAD⁻), dead (mitopotential⁺/7-AAD⁺), and depolarized dead (mitopotential⁻/7-AAD⁺) were measured using Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA), according to manufacturer's instruction.

Apoptosis Assay

The number and percentage of cells undergoing apoptosis were determined using Muse[®] Annexin V & Dead Cell Kit, EMD Millipore Co. (Billerica, MA, USA) according to the manufacturer's instructions and as described previously.¹⁴ Briefly, 80% confluent MDA-MB-231 cells were incubated for 24 h with VCX (10, 25, and 50 µM). The cells were collected by trypsinization, centrifuged at 300×g for 5 min, and then resuspended in 100 µL 1% FBS followed by incubation with Muse[®] Annexin V & Dead Cell reagent in the dark. The percentage of healthy, apoptotic, and dead cells was counted with the Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA).

Caspase 3/7 Activities

The quantitative measurements of apoptotic status based on caspase 3/7 activation were examined using Muse[®] Caspase 3/7 Activation Kit, EMD Millipore Co. (Billerica, MA, USA), as described previously.¹⁵ Briefly, after 24 h treatment with VCX, cells were trypsinized,

centrifuged at 300×g for 5 min, and then resuspended in 1X Assay Buffer, followed by incubation with 5 µL of caspase 3/7 reagent working solution for 30 min at 37°C in 5% of CO₂ incubator. After incubation, 150 µL of Muse[®] Caspase 7-ADD working solution was added and incubated at room temperature for 5 min in the dark. The percentage of caspase 3/7 positive cells was measured using Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

After 24 h of treatment, total cellular RNA was isolated by a standard TRIzol method, Invitrogen Co. (Grand Island, NY, USA). The isolated RNA quantity and quality were maintained at 260/280 ratio of 1.8–2.0 using NanoDrop[®] 8000 spectrophotometer, Thermo Fisher Scientific Inc. (Waltham, MA, USA). High-Capacity cDNA Reverse Transcription kit was used for cDNA synthesis in a Veriti[®] Thermal cyclers (Applied Biosystems[®]).¹⁶ The mRNA expression levels of the target genes were quantified in QuantStudio[®] 6 Flex Real-Time PCR System (Applied Biosystems[®]) using SYBR Green Universal Mastermix.¹⁷ Human primers for caspase 3, caspase 7, heme oxygenase-1 (HO-1), glutathione S Transferase A (GSTA), cyclin D1, E2F1, LC3, Beclin1, and β-actin (Table 1) were obtained from Integrated DNA Technologies (Coralville, IA, USA). The qRT-PCR data were analyzed using ΔΔCT method.¹⁸

Protein Extraction and Western Blot Analysis

Total protein isolated from MDA-MB-231 cells was quantified by Infrared (IR) spectroscopy Direct Detect[®], EMD Millipore Co. (Billerica, MA, USA).²⁴ Western blot analysis was performed as described before²⁴ by separating approximately 30 µg protein in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and then transferred to a nitrocellulose membrane, Bio-Rad (Mississauga, ON, Canada). The protein blots were blocked overnight at 4°C, followed by incubation, at 4°C, with primary antibodies against target proteins followed by incubation with appropriate peroxidase-conjugated secondary antibody for 2 h at room temperature. The bands were visualized by chemiluminescence kits, EMD Millipore Co. (Billerica, MA, USA) using

Table 1 Primers Sequences Used for qRT-PCR Reactions

Gene	5'→3' Forward Primer	5'→3' Reverse Primer	Reference
<i>β-actin</i>	CCAGATCATGTTTGAGACCTTCAA	GTGGTACGACCAGAGGCATACA	[19]
<i>Caspase 3</i>	CGCAGACCTTGTGATATTCCAG	CGTTTCTTCCATCCTTCCAGG	[20]
<i>Caspase 7</i>	TGAGCCACGGAGAAGAGAAT	TTTGCTTACTCCACGGTTCC	[21]
<i>HO-1</i>	ATGGCCTCCCTGTACCACATC	TGTTGCGCTCAATCTCCTCCT	[19]
<i>GSTA</i>	TTGATGTTCCAGCAAGTGCC	CACCAGCTTCATCCCATCAAT	[20]
<i>Cyclin D1</i>	GATAGCCTTCGACCCAAGCA	ATGGCGGTGAGTGTCAGGAT	[20]
<i>E2F1</i>	ATGTTTTCTGTGCCCTGAG	ATCTGTGGTGAGGGATGAGG	[22]
<i>LC3</i>	CATGAGCGAGTTGGTCAAGAT	TCGTCTTCTCCTGCTCGTAG	[23]
<i>Bedlin1</i>	TGAGGGATGGAAGGGTCTAAG	GCCTGGGCTGTGGTAAGTAATC	[23]

C-DiGit[®] Blot Scanner, LI-COR Biosciences (Lincoln, NE, USA).

Cell Cycle Distribution and Progression Analysis

Cell cycle distribution and progression were analyzed using Muse[®] Cell Cycle Kit, EMD Millipore Co. (Billerica, MA, USA).¹⁴ Briefly, cells treated with VCX for 24 h were collected by trypsinization, centrifuged at 300×g for 5 min, and then resuspended in phosphate-buffered saline followed by incubation with 70% cold ethanol at −20°C for at least 30 min prior to staining with a premixed reagent propidium iodide (PI) and RNase A. The DNA contents at all cell cycle stages were quantified using Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA).

Reactive Oxygen Species (ROS) Production Assay

The cellular population undergoing oxidative stress was detected by measuring the levels of reactive oxygen species (ROS) using Muse[®] Oxidative Stress Kit, EMD Millipore Co. (Billerica, MA, USA), as described previously²⁵ and according to the manufacturer's instructions. Briefly, pelleted cells treated with VCX were stained with Muse[®] Oxidative Stress Working Solution that contains dihydroethidium (DHE), which is permeable and can react with superoxide anions undergoes oxidation to form the DNA-binding fluorophore ethidium bromide. The fluorescence produced was measured using Muse[®] Cell Analyzer, EMD Millipore Co. (Billerica, MA, USA).

Statistical Analysis

The statistical analysis of the results was performed using Sigma Stat[®] for Windows, Systat Software Inc. (San Jose,

CA, USA). Student's *t*-test or one-way analysis of variance (ANOVA) followed by Student–Newman–Keul's (SNK) tests were performed and the differences were considered significant when *p* < 0.05.

Results

Effect of VCX Treatment on the Proliferation and Growth of Different Types of Breast Cancer Cell Lines

We first assessed the ability of VCX to inhibit the growth and proliferation of three breast cancer cell lines of different molecular subtypes, SKBR-3 (HER2+), MCF-7 (ER+), and MDA-MB-231 (TNBC). The cells were incubated for 24 h with wide range of VCX concentrations (0.5, 1, 2.5, 5, 10, 25, 50, and 100 μM), those concentrations were selected based on previous studies,^{10,13} after that cell proliferation was determined as described in the Materials and Methods section. Figure 1A shows that VCX at concentrations up to 5 μM did not significantly alter cell viability and proliferation of all tested cells. However, a significant decrease in cell proliferation was observed at VCX concentrations 10, 25, 50, and 100 μM in all tested cells in a concentration-dependent manner (Figure 1A). The IC₅₀ of VCX for MDA-MB-231 was approximately 60 ± 4.2 μM, whereas MCF-7 and SKBR-3 cells were more sensitive to VCX inhibitory effects with IC₅₀ of 36 ± 5.3 and 34 ± 7.1 μM, respectively (Figure 1A). Based on cell viability/proliferation studies, the concentrations 10, 25, and 50 μM have been selected to be utilized in all subsequent studies using TNBC MDA-MB-231 cell line as a study model.

Effect of VCX Treatment on Cell Mitochondrial Potential and Cellular Plasma Membrane Permeabilization

Depolarization of the mitochondrial membrane potential prevents calcium entry into the mitochondria causing cell

Figure 1 Effect of VCX on the proliferation and growth of human breast cancer cells. **(A)** Human breast cancer cell lines; SKBR-3, MCF-7, and MDA-MB-231 cells were treated for 24 h with a wide range of VCX concentrations. Cell proliferation and viability were determined by Muse[®] Count & Viability assay. **(B)** MDA-MB-231 cells were treated with VCX (10, 25, and 50 μM) for 24 h. Thereafter, the percentages of live, depolarized, and dead cells were determined by Muse[®] MitoPotential Kit using Muse[®] Cell Analysis. The histogram represents the mean, ($n = 3$, triplicate). * $P < 0.05$ compared to control, VCX=0 μM , (ANOVA followed by SNK test).

viability reduction, and this is considered as an indicator for early apoptosis. To test whether the inhibitory effect of VCX on MDA-MB-231 cell proliferation is due to the depolarization of the mitochondria membrane, we examined the effect of VCX on the mitochondrial potential and cellular plasma membrane permeabilization, a marker for cell death.²⁶ For this purpose, MDA-MB-231 cells were treated for 24 h with VCX (10, 25, and 50 μ M), and then the percentage of live cells with intact mitochondria, depolarized live and dead cells, and dead cells with intact mitochondria were determined by flow cytometry. Figure 1B shows that VCX treatment at 10 μ M concentration did not significantly alter the mitopotential and membrane permeability. However, higher VCX concentrations (25 and 50 μ M) significantly increased the percentage of depolarized (live and dead) cells up to 27% and 48%, respectively, as compared to the control (8%). In addition, the percentage of live cells was significantly decreased to 38% at the highest concentration tested (50 μ M) (Figure 1B).

Effect of VCX Treatment on Apoptosis

To explore the mechanisms of the VCX inhibitory effect on MDA-MB-231 cell growth and proliferation, we investigated whether this effect could be attributed to increased apoptotic and/or necrotic cell population. Treatment of MDA-MB-231 cells for 24 h with VCX (10, 25, and 50 μ M) significantly increased the percentages of apoptotic cells (early and late) at all tested concentrations, in a concentration-dependent manner, by approximately 2-, 4-, and 6-fold, respectively, as compared to the control (Figure 2).

To further examine whether increased the percentage of apoptotic cells by VCX treatment is associated with changes in the activity and expression of pro-apoptotic and anti-apoptotic markers, we measured the effect of 24 h treatment of VCX on the expression of caspases 3/7, BAX, and BCL-2 in MDA-MB-231 cells. Our results show that VCX 25 and 50 μ M treatment significantly increased caspases 3/7 activity using flow cytometry (Figure 3A) and

Figure 2 Effect of VCX treatment on the apoptosis level in MDA-MB-231 cells. MDA-MB-231 cells were treated for 24 h with VCX (10, 25, and 50 μ M). Thereafter, the percentage of cell undergoing apoptosis were determined using Muse[®] Annexin V & Dead Cell Kit. The histogram represents the mean, (n = 3, triplicate). *P < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test).

Figure 3 Effect of VCX treatment on the activity and expression of pro- and anti-apoptotic markers in MDA-MB-231 cells. MDA-MB-231 cells were treated for 24 h with VCX (10, 25, and 50 μM). **(A)** The percentage of cells expressing caspases 3/7 was determined using Muse® Caspases 3/7 Kit. The histogram represented the mean, (n = 3, triplicate). *P < 0.05 compared to control, VCX=0 μM, (ANOVA followed by SNK test). **(B)** Caspases 3 and 7 mRNA levels were quantified using qRT-PCR and normalized to β-actin housekeeping gene. Triplicate reactions were performed for each experiment. The values represented the mean of fold change ± SEM, (n = 6). *P < 0.05 compared to control, VCX=0 μM, (ANOVA followed by SNK test). **(C)** caspase 3, BAX and BCL-2 protein levels were determined by Western blot analysis. One of three representative experiments is shown. The values represented the mean of fold change ± SEM, (n = 3). *P < 0.05 compared to control, VCX= 0 μM, (ANOVA followed by SNK test). **(D)** Histogram represents BAX/BCL-2 ratio.

their mRNA (Figure 3B) levels in a concentration-dependent manner. At the protein level, VCX treatment induced the pro-apoptotic caspase 3 and BAX proteins by approximately 6- and 5-fold, respectively, whereas dramatically inhibited the anti-apoptotic BCL-2 protein by more than 65% at the highest concentrations tested, 50 μ M (Figure 3C). The BAX: BCL-2 ratio was increased by VCX in a concentration-dependent manner reached up to 7- and 14-folds at concentrations 25 and 50 μ M, respectively (Figure 3D).

Effect of VCX Treatment on Cell Cycle Phases and Genes

To examine whether the arrest of the cell cycle is contributing to the inhibitory effect of VCX on MDA-MB-231 cell proliferation and growth, we performed a cell cycle analysis by flow cytometry. Figure 4A shows that VCX treatment caused changes in cell cycle progression at all tested concentrations. For example, VCX 50 μ M

Figure 4 Effect of VCX treatment on MDA-MB-231 cell cycle phases and genes. MDA-MB-231 cells were treated for 24 h with various concentration of VCX (10, 25, and 50 μ M). (A) Cell cycle phases were determined by Muse[®] Cell Cycle assay. Values are presented as the mean of percentage of live cells (n = 3, triplicate). (B) Cyclin D1 and E2F1 mRNA levels were quantified using qRT-PCR and normalized to β -actin housekeeping gene. Triplicate reactions were performed for each experiment. The values represented the mean of fold change $\pm$ SEM, (n = 6). *P < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test). (C) Cyclin D1 and E2F1 protein expression levels were determined by Western blot analysis. One of three representative experiments is shown. The values represented the mean of fold change $\pm$ SEM, (n = 3). *P < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test).

significantly increased the percentage of cell population in the G0/G1 phase to 65% (50% increase) as compared to control (43%), whereas decreased cell population in the S phase to 16% (50% decrease) as compared to control (34%). No significant changes in G2/M phase were observed in response to VCX treatment (Figure 4A).

To further determine whether the cell cycle arrest by VCX is attributed to a downregulation in the expression of cell cycle proliferative genes, we quantified the mRNA and protein expression levels of cyclin D1 and E2F1, well-known cell cycle genes, by qRT-PCR and Western blot analyses, respectively. Data in Figure 4B illustrate that VCX significantly inhibited cyclin D1 and E2F1 mRNA expression by approximately 55% and 70%, respectively, at VCX 50 μ M concentration. At the protein expression level, cyclin D1 and E2F1 proteins were markedly inhibited by all tested VCX concentrations, reached up to 90% by VCX 50 μ M as compared to control (Figure 4C).

Effects of VCX Treatment on Oxidative Stress

We tested the role of oxidative stress in VCX inhibitory effect on cell proliferation by first measuring the percentage of MDA-MB-231 cells generating ROS and second by quantifying the mRNA and protein expression levels of oxidative stress-mediated genes, HO-1 and GSTA. The flow cytometry analysis data in Figure 5A show that VCX 25 and 50 μ M treatment significantly increased the percentage of cells generating ROS to 9% and 11%, respectively, as compared to 5% in control cells. The increased ROS formation was associated with a concentration-dependent induction of HO-1 and GSTA mRNA (Figure 5B) and protein (Figure 5C) expression levels.

Effect of VCX on Cell Autophagy

The possibility that VCX induces cell apoptosis via an autophagy-mediated cell death was tested by measuring the mRNA and protein expression of well-known markers of cell autophagy (LC3 and Beclin1)²⁷ in response to VCX 25 μ M. Figure 6A shows that VCX induced autophagy-associated cell death through increasing the mRNA expression of LC3 and beclin1 by approximately 30% and 40%, respectively. This was confirmed at the protein expression level, where VCX increased the expression of LC3II protein level by 3-fold (Figure 6B).

Effect of VCX on the Chemo-Sensitivity of MDA-MB-231 Cells to DOX

To test whether VCX would increase the chemo-sensitivity of MDA-MB-231 cells to chemotherapy, we examined the effect of VCX treatment in combination with DOX on MDA-MB-231 apoptosis level as a marker for chemo-sensitivity. Cells were treated for 24 h with VCX (25 μ M) in the presence and absence of DOX (100 nM). Then, the percentage of cells that underwent apoptosis/necrosis was determined by flow cytometry. VCX or DOX monotherapy increased the percentage of apoptotic cells to 23% and 20%, respectively, as compared to control (8%). Importantly, DOX and VCX combination therapy synergistically increased the percentage of apoptotic cells to 71% as compared to DOX alone (Figure 7).

Discussion

The predominant role of BCL-2 family is to regulate cell survival by modulating the integrity and the release of apoptogenic factors.²⁸ Not surprisingly, BCL-2 over-expression has been linked to tumorigenesis initiation and the development of resistance to chemotherapies.²⁹ Due to their regulatory roles in apoptosis, members of the BCL-2 family are considered as promising targets for cancer therapy.^{28,29} VCX is a potent and selective BCL-2 inhibitor with anti-tumor properties that usually correlates with its inhibitory effect on BCL-2. With increased BCL-2 expression in BC and particularly in TNBC, the possibility that VCX may suppress TNBC proliferation could not be ruled out. The available studies on the effect of VCX on BC cells proliferations only investigated the role of apoptosis, whereas the involvement of other mechanisms such as autophagy, cell cycle arrest, and oxidative stress has not been investigated. Therefore, the main objective of the current study was to explore the mechanistic role of autophagy, cell cycle arrest, and oxidative stress in VCX-induced breast cancer cell proliferation and growth inhibition.

The present study demonstrates the ability of VCX to cause a concentration-dependent cell growth inhibition in three breast cancer cell lines that pose different molecular subtypes, MCF-7 (ER+), SKBR-3 (HER-2+), and MDA-MB-231 (TNBC). Cell growth inhibition of VCX was more effective on both MCF-7 and SKBR-3 cells than on MDA-MB-231, with IC₅₀ of approximately 35 μ M

Figure 5 Effect of VCX treatment on oxidative stress in MDA-MB-231 cells. MDA-MB-231 cells were treated for 24 h with various concentrations of VCX (10, 25, and 50 μ M). **(A)** Production of ROS was determined by Muse[®] Oxidative Stress Kit. The values represented the mean $\pm$ SEM, (n = 3, triplicate). * P < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test). **(B)** HO-1 and GSTA mRNA levels were quantified using qRT-PCR and normalized to β -actin housekeeping gene. The values are presented as mean $\pm$ SEM, (n = 6, triplicate). * P < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test). **(C)** HO-1 and GSTA protein expression levels were determined by Western blot analysis. One of three representative experiments is shown. The values represented the mean $\pm$ SEM, (n = 3). * p < 0.05 compared to control, VCX=0 μ M, (ANOVA followed by SNK test).

for MCF-7 and SKBR-3 and 60 μ M for MDA-MB-231 cells. The differential sensitivity of the cells to VCX could be attributed to several factors including the expression level of BCL-2. For example, BCL-2 is overexpressed in 85% of cases of luminal cancers (ER+),³⁰ whereas overexpressed in approximately 41% of TNBC cases,⁵ which could explain the least sensitivity of MDA-MB-231 cells to VCX. The in vitro concentrations of VCX used in this study were maintained close to the therapeutic range of

plasma concentration reported in humans.³¹ However, using higher VCX concentrations in the current study is attributed to the excessive concentrations of glucose, FBS, growth factors which all stimulate cell growth to promote breast cancer aggression and aggressiveness of TNBC.³² Other possible factors include the presence of an oncogenic mutation in the cell culture system, which reduces the efficacy of VCX concentrations required to achieve the anti-cancer effects.

Figure 6 Effect of VCX treatment on autophagy in MDA-MB-231 cells. MDA-MB-231 cells were treated for 24 h with VCX (25 μM). (A) LC3 and Beclin1 mRNA levels were quantified using qRT-PCR and normalized to β-actin housekeeping gene. The values are presented as mean ± SEM, (n = 6, triplicate). *P < 0.05 compared to control, VCX=0 μM, (Student's t-test). (B) LC3I and II protein levels were determined by Western blot analysis. One of three representative experiments is shown. The values are presented as mean ± SEM. *p < 0.05 compared to control, VCX=0 μM, (Student's t-test).

In MDA-MB-231 cells, the ability of VCX treatment to induce mitochondrial dysfunction and membrane permeabilization is substantial evidence

supporting VCX-induced apoptosis in a mitochondria-mediated pathway. The possibility that VCX exhibits anti-proliferative effects on MDA-MB-231 cells through induction of apoptosis was supported by the ability of VCX to a) increase the percentage of MDA-MB-231 cells undergo apoptosis and induce caspase 3/7 activity and gene expression at the mRNA and protein levels and b) induce the expression of several pro-apoptotic markers, caspase 3, caspase 7, BAX, while inhibit the expression of the anti-apoptotic BCL-2 with increased BAX/BCL-2 ratio. Our findings are in an agreement with previous observations, which showed that VCX induces apoptosis¹⁰ in breast cancer cells through BAX-dependent mechanism.^{33,34} Increased cell apoptosis by VCX in the current study was associated with induction of cell cycle arrest in G0/G1, leading to an increase in the percentage of cells in the G0/G1 phase with a decrease in the S phase cell population. The probable mechanism mediating the cell cycle arrest by VCX is the downregulation of positive regulators of G1-to-S transition including cyclin D1

Figure 7 Effect of VCX on the chemo-sensitivity of MDA-MB-231 cells to DOX. MDA-MB-231 cells were treated for 24 h with VCX 25 μM alone or in combination with DOX 100 nM. Thereafter, the percentage of cell underwent apoptosis were determined using Muse® Annexin V & Dead Cell Kit. The values are presented as mean, (n = 3, triplicate). *P < 0.05 compared to control, VCX=0 μM, #P < 0.05 compared to DOX, (ANOVA followed by SNK test).

though the inhibition of E2F1 transcription factor that is known to regulate cyclin D1 promoter.³⁵ Although the exact mechanism of downregulation of cyclin D1 by VCX was not explored in this study, increased cyclin D1 degradation post-translationally by ubiquitination or phosphorylation is postulated,³⁶ however further studies are needed. These findings agree with earlier studies showing that overexpression of cyclin D1 gene was observed steadily in breast tumors.^{37,38} In addition, it has been proposed that cellular senescence, which is a permanent cell cycle arrest in G0/G1 in response to different stressors, contributes to tumor suppression.^{39,40}

Another possible mechanism that could regulate VCX-induced apoptosis is oxidative stress.⁴¹ In this context, we report here that VCX-induced apoptosis was proportionally associated with a significant increase in ROS production and the expression of oxidative stress marker genes, HO-1 and GSTA, at both the mRNA and protein levels. Despite the fact that BCL-2 overexpression promotes cancer cell survival, recent reports provide evidence that the BCL-2 family also involves a redox component.⁴² Previous observations support our current results in which these studies showed that inhibition of cancer cells proliferation and induction of apoptosis and cell cycle arrest are mediated by induction of oxidative stress genes probably via the activation of ubiquitin-dependent proteasome degradation of cyclin D1.⁴³ Importantly, induction of oxidative stress by VCX is believed to mediate the activation of autophagy-associated cell death pathway markers, LC3II and Beclin1, at the mRNA and protein levels. To our knowledge, this is the first report to demonstrate the inter-relationship between induction of apoptosis and autophagy-associated cell death by VCX-mediated inhibition of BCL-2 in MDA-MB-231 cells. In this regard, it was reported that Beclin1, an essential initiator of autophagy pathway, has a BCL-2 homology (BH3) domain. Interaction of BCL-2 protein with Beclin1 BH3 domain prevents assembling of the pre-autophagosome structure leading to autophagy inhibition, indicating that downregulation of BCL-2 by VCX is the first step toward activation of autophagy-associated cell death pathway.⁴⁴ The dual induction of apoptosis and autophagic-associated cell death makes VCX an ideal chemotherapeutic target for breast cancer.

DOX and other anthracyclines trigger a DNA damage response and subsequently activate an apoptotic pathway

to kill cancer cells.^{45,46} Since BCL-2 family plays a significant role in regulating apoptotic cell death, it is possible that inhibition of BCL-2 restores sensitivity to chemotherapeutic agents. The present findings show that the combination of VCX with DOX increases the chemosensitivity of MDA-MB-231 to DOX, and this could provide a new strategy to overcome the protective effects of BCL-2 and hence deliver efficacious therapies. These findings also suggest the potential of VCX to be used clinically to increase the efficacy of DOX and other chemotherapeutic agents.

Conclusions

The present study demonstrates strong evidence that VCX a) induces human triple-negative breast cancer MDA-MB-231 cell growth inhibition through apoptosis, cell cycle arrest, autophagy-associated cell death, and oxidative stress mechanisms and b) increases the chemosensitivity to DOX in MDA-MB-231 cells.

Funding

The authors are very grateful to the Office of Research Support at Qatar University (grants # IRCC-2019-006, QUCG-CPH-20/21-1, QUST-2-CPH-2020-3) and the Qatar Foundation – Qatar National Research Fund (grant # UREP24-163-3-049) for funding this study. Open access funding was provided by the Qatar National Library.

Disclosure

The authors declare there is no conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. There are no financial or other interests with regard to this manuscript that might be construed as a conflict of interest. All of the authors are aware of and agree to the content of the manuscript and their being listed as an author on the manuscript. The abstract of this paper was presented at the Experimental Biology 2019 Meeting as a poster presentation with interim findings. The poster's abstract was published in "Experimental Biology 2019 Meeting Abstract" in the FASEB Journal 2019: https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2019.33.1_supplement.674.16.

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65(1):5–29. doi:10.3322/caac.21254
- Akhtar S, Hourani S, Therachiyil L, et al. Epigenetic regulations of cancer stem cells by the aryl hydrocarbon receptor pathway. *Semin Cancer Biol*. 2020. doi:10.1016/j.semcancer.2020.08.014
- Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. *JAMA*. 2010;304(4):426–434. doi:10.1001/jama.2010.1042
- Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018;5(2):77–106. doi:10.1016/j.gendis.2018.05.001
- Merino D, Lok SW, Visvader JE, Lindeman GJ. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. *Oncogene*. 2016;35(15):1877–1887. doi:10.1038/ncr.2015.287
- Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. Bcl2 as a subtype-specific prognostic marker for breast cancer. *J Breast Cancer*. 2016;19(3):252–260. doi:10.4048/jbc.2016.19.3.252
- Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. *Oncogene*. 2008;27(Suppl 1):S149–157. doi:10.1038/ncr.2009.52
- Li Q, Cheng L, Shen K, et al. Efficacy and safety of Bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials. *Front Pharmacol*. 2019;10:697. doi:10.3389/fphar.2019.00697
- Gibson CJ, Davids MS. BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. *Clin Cancer Res*. 2015;21(22):5021–5029. doi:10.1158/1078-0432.CCR-15-0364
- Inao T, Iida Y, Moritani T, et al. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. *Oncotarget*. 2018;9(39):25545–25556. doi:10.18632/oncotarget.25370
- Sun Q, Wang Y, Desgrosellier JS. Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells. *Cancer Lett*. 2019;457:40–46. doi:10.1016/j.canlet.2019.05.004
- Zhou W, Feng X, Han H, Guo S, Wang G. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. *Sci Rep*. 2016;6:28004.
- Lucantoni F, Dussmann H, Llorente-Folch I, Prehn JHM. BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose. *Oncotarget*. 2018;9(40):26046–26063. doi:10.18632/oncotarget.25433
- Szumilak M, Galdyszyńska M, Dominska K, Stanczak A, Piastowska-Ciesielska A. Anticancer activity of some polyamine derivatives on human prostate and breast cancer cell lines. *Acta Biochim Pol*. 2017;64(2):307–313. doi:10.18388/abp.2016_1416
- Kuroda K, Fukuda T, Isogai H, Okumura K, Krstic-Demonacos M, Isogai E. Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile. *Int J Oncol*. 2015;46(4):1516–1526. doi:10.3892/ijo.2015.2887
- Alhoshani A, Alanazi FE, Alotaibi MR, et al. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN/Akt/FoxO3a pathway and reactive metabolites formation: in vivo and in vitro rat studies. *Chem Res Toxicol*. 2020;33(7):1719–1728. doi:10.1021/acs.chemrestox.0c00005
- Korashy HM, Attafi IM, Ansari MA, et al. Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: role of apoptosis and oxidative stress. *Toxicol Lett*. 2016;252:50–61. doi:10.1016/j.toxlet.2016.04.011
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. *Methods*. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
- Korashy HM, Maayah ZH, Al Anazi FE, et al. Sunitinib inhibits breast cancer cell proliferation by inducing apoptosis, cell-cycle arrest and DNA repair while inhibiting NF-kappaB signaling pathways. *Anticancer Res*. 2017;37(9):4899–4909.
- Korashy HM, Belali OM, Ansar MA, Alharbi NO. FoxO3a is essential for the antiproliferative and apoptogenic effects of sunitinib in MDA-MB231 cell line. *Anticancer Res*. 2016;36(11):6097–6108. doi:10.21873/anticancer.11200
- Liu W, Hu M, Wang Y, et al. Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3beta signaling. *Oncol Rep*. 2015;33(3):1049–1056. doi:10.3892/or.2015.3724
- Hossain S, Iwasa H, Sarkar A, Maruyama J, Arimoto-Matsuzaki K, Hata Y. The RASSF6 tumor suppressor protein regulates apoptosis and cell cycle progression via retinoblastoma protein. *Mol Cell Biol*. 2018;38(17):17. doi:10.1128/MCB.00046-18
- Wu ZZ, Zhang JJ, Gao CC, et al. Expression of autophagy related genes mTOR, beclin-1, LC3 and p62 in the peripheral blood mononuclear cells of systemic lupus erythematosus. *Am J Clin Exp Immunol*. 2017;6(1):1–8.
- Korashy HM, El-Kadi AO. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. *Toxicology*. 2004;201(1–3):153–172. doi:10.1016/j.tox.2004.04.011
- CAT E, Bradner JM, Moser A, et al. Assessing reproductive toxicity of two environmental toxicants with a novel in vitro human spermatogenic model. *Stem Cell Res*. 2015;14(3):347–355. doi:10.1016/j.scr.2015.03.002
- Galluzzi L, Kepp O, Kroemer G. Mitochondrial regulation of cell death: a phylogenetically conserved control. *Microb Cell*. 2016;3(3):101–108. doi:10.15698/mic2016.03.483
- Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. *Cancer Discov*. 2019;9(9):1167–1181. doi:10.1158/2159-8290.CD-19-0292
- Schenk RL, Strasser A, Dewson G. BCL-2: long and winding path from discovery to therapeutic target. *Biochem Biophys Res Commun*. 2017;482(3):459–469. doi:10.1016/j.bbrc.2016.10.100
- Fernandez-Luna JL. Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance. *Cell Signal*. 2008;20(11):1921–1926. doi:10.1016/j.cellsig.2008.04.015
- Tekedereli I, Alpaz SN, Akar U, et al. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. *Mol Ther Nucleic Acids*. 2013;2:e121. doi:10.1038/mtna.2013.45
- Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. *J Clin Oncol*. 2017;35(8):826–833. doi:10.1200/JCO.2016.70.4320
- Wahdan-Alaswad R, Fan Z, Edgerton SM, et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. *Cell Cycle*. 2013;12(24):3759–3769. doi:10.4161/cc.26641
- Vela L, Gonzalo O, Naval J, Marzo I. Direct interaction of bax and bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. *J Biol Chem*. 2013;288(7):4935–4946. doi:10.1074/jbc.M112.422204
- Ding J, Zhang Z, Roberts GJ, et al. Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif. *J Biol Chem*. 2010;285(37):28749–28763. doi:10.1074/jbc.M110.148361
- Rezaei PF, Fouladdel S, Ghaffari SM, Amin G, Azizi E. Induction of G1 cell cycle arrest and cyclin D1 down-regulation in response to pericarp extract of Baneh in human breast cancer T47D cells. *Daru*. 2012;20(1):101.

36. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. *Cancer Res.* 2009;69(16):6565–6572. doi:10.1158/0008-5472.CAN-09-0913
37. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. *Nat Rev Mol Cell Biol.* 2002;3(1):11–20. doi:10.1038/nrm714
38. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature.* 2001;411(6835):342–348.
39. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. *Genes Dev.* 2010;24(22):2463–2479. doi:10.1101/gad.1971610
40. Campisi J, d'Adda Di Fagagna F. Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol.* 2007;8(9):729–740. doi:10.1038/nrm2233
41. West JD, Marnett LJ. Endogenous reactive intermediates as modulators of cell signaling and cell death. *Chem Res Toxicol.* 2006;19(2):173–194. doi:10.1021/tx050321u
42. Cho HD, Lee JH, Jeong JH, et al. Production of novel vinegar having antioxidant and anti-fatigue activities from *Salicornia herbacea* L. *J Sci Food Agric.* 2016;96(4):1085–1092.
43. Hill M, Pereira V, Chauveau C, et al. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. *FASEB J.* 2005;19(14):1957–1968. doi:10.1096/fj.05-3875com
44. Marquez RT, Xu L. Bcl-2: beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. *Am J Cancer Res.* 2012;2(2):214–221.
45. Yang MC, Lin RW, Huang SB, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. *Cell Cycle.* 2016;15(3):394–402. doi:10.1080/15384101.2015.1127470
46. Takahashi M, Saito H, Atsukawa K, Ebinuma H, Okuyama T, Ishii H. Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. *Hepatol Res.* 2003;25(2):192–201. doi:10.1016/S1386-6346(02)00244-9

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>